Swift Biosciences is a technology company.
Swift Biosciences has raised $10.0M across 2 funding rounds.
Swift Biosciences has raised $10.0M in total across 2 funding rounds.
Swift Biosciences has raised $10.0M in total across 2 funding rounds.
Swift Biosciences's investors include Mercury Fund.
Swift Biosciences is a biotechnology company that develops and commercializes next-generation sequencing (NGS) library preparation kits, enabling faster, more sensitive analysis for genomics, translational, and clinical research.[1][2][5] These kits target researchers and labs by solving challenges in sample preparation for whole genome sequencing and targeted applications, such as amplicon sequencing, allowing higher throughput at lower costs per sample.[1][4][6] The company achieved significant growth momentum through product innovation and global expansion before its acquisition by Integrated DNA Technologies (IDT) in March 2021, after which its technologies integrated into IDT's xGen™ NGS portfolio.[3][4]
Swift Biosciences emerged from advancements in NGS library preparation, founded to address inefficiencies in genomic sequencing workflows.[1][5] Backed by venture capital from firms like Arboretum Ventures, the company focused on novel technologies for efficient, highly sensitive kits, gaining early traction in academic and research settings.[4][6] A pivotal moment came with the launch of its Amplicon technology and expansions, including accelerated global growth in China and Asia-Pacific markets prior to acquisition.[2][7] Post-2021 acquisition by IDT (part of Danaher Corporation), Swift's products transitioned seamlessly into a broader NGS ecosystem, marking its evolution from standalone innovator to integrated player.[3][4]
Swift Biosciences stood out in the NGS space through these key strengths:
Swift Biosciences rode the explosive growth of NGS in precision medicine, where demand for scalable, cost-effective library prep fuels genomics research, cancer profiling, and microbiome studies.[1][2][3] Its timing aligned with surging needs for high-throughput sequencing amid falling genome costs and rising clinical applications, amplified by market forces like increased R&D in translational research.[6] By pioneering efficient kits, Swift influenced the ecosystem, paving the way for integrated solutions post-acquisition, enhancing tools available to labs worldwide and accelerating discoveries in spatial transcriptomics and organoid development.[2][3]
Post-acquisition, Swift Biosciences' technologies thrive within IDT's xGen™ NGS portfolio, poised for deeper integration into Danaher's life sciences platform with expansions in CRISPR, tumor profiling, and beyond.[3] Trends like AI-driven genomics analysis and multi-omics will amplify its impact, driving demand for its sensitive, rapid kits amid booming personalized medicine markets. Expect evolving influence through enhanced developer tools and cGMP services, solidifying its role in faster, more accessible research—echoing its origins as a pioneer in efficient NGS prep.[2][3][7]
Swift Biosciences has raised $10.0M across 2 funding rounds. Most recently, it raised $7.0M Series B in October 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2013 | $7.0M Series B | Mercury Fund | |
| Aug 1, 2010 | $3.0M Series A | Mercury Fund |